Colombia

In Colombia, the primary regulatory authority for health products is INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), operating under the oversight of the Ministry of Health and Social Protection (Ministerio de Salud y Proteccion Social). The principal governing legislation includes Decree 677 of 1995 for pharmaceuticals, Decree 4725 of 2005 for medical devices and diagnostics, and Resolution 1403 of 2007 for pharmaceutical management standards. INVIMA is responsible for granting sanitary registrations (Registros Sanitarios) and surveillance notifications (Notificaciones Sanitarias Obligatorias, NSOs) depending on the risk classification of the product. Medical devices are classified into four risk tiers (I, IIA, IIB, III), with higher-risk products requiring full sanitary registration and lower-risk items eligible for a simplified NSO pathway. Digital health products are an emerging category subject to evolving guidance, with INVIMA increasingly applying software-as-a-medical-device frameworks.

All applicants seeking market authorization in Colombia must appoint a legally established local representative or holder (titular del registro sanitario) domiciled in Colombia, who assumes full regulatory and legal responsibility for the product. Dossier submissions broadly follow the Common Technical Document (CTD) structure, and INVIMA accepts data packages prepared to ICH, IMDRF, and PAHO/WHO standards depending on product type. Colombia is a member of the Pan American Network for Drug Regulatory Harmonization (PANDRH) and increasingly references agreements within the Pacific Alliance (Alianza del Pacifico) to facilitate mutual recognition and expedited review pathways. Notable recent reforms include Resolution 2022 of 2022, which updated post-market surveillance requirements, and ongoing digitalization of INVIMA's VITAL platform for electronic submissions, aiming to reduce review backlogs and improve transparency in registration timelines.

Public procurement of health products in Colombia is administered through a multi-tiered structure. The Ministry of Health and Social Protection sets national health policy and benefit plan coverage decisions through the Plan de Beneficios en Salud (PBS), while the national health insurer body ADRES (Administradora de los Recursos del Sistema General de Seguridad Social en Salud) manages funding flows. Public procurement is governed by Law 80 of 1993 and Law 1150 of 2007, with processes conducted through Colombia Compra Eficiente, the national public procurement authority, and published on the SECOP (Sistema Electronico de Contratacion Publica) platform. Health products reimbursed under the PBS, including those on the exclusions list managed via Resolution mechanisms, are subject to price controls established by the Comision Nacional de Precios de Medicamentos y Dispositivos Medicos (CNPMDM). Departmental and municipal health secretariats also conduct their own procurement processes for public health programs, creating a federated but centrally regulated procurement ecosystem.

The private sector represents a substantial share of health product consumption in Colombia, driven by a large network of private clinics, hospital chains, pharmacies, and health maintenance organizations (EPS, Entidades Promotoras de Salud). Distributor and wholesaler networks play a critical intermediary role in reaching both private and subsidized-regime institutions. International donor and multilateral channels are less dominant than in lower-income regional peers, but organizations such as PAHO/WHO, UNICEF, and USAID do support specific public health programs, including immunization supply chains and communicable disease control initiatives. The government has introduced policies to encourage local pharmaceutical and device manufacturing under frameworks such as Decreto 1782 of 2014, which established procedures recognizing products manufactured in countries with stringent regulatory authorities (SRAs), and ongoing discussions within the Pacific Alliance promote regional supply chain integration. Local manufacturing preference clauses, while not uniformly mandated, are increasingly factored into public tender criteria to support domestic industrial capacity.